Compare ANPA & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | INO |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | Hong Kong | United States |
| Employees | 32 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 90.5M |
| IPO Year | N/A | 1999 |
| Metric | ANPA | INO |
|---|---|---|
| Price | $4.60 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 5.4K | ★ 1.6M |
| Earning Date | 02-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $2.80 | $1.03 |
| 52 Week High | $180.64 | $2.86 |
| Indicator | ANPA | INO |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 43.12 |
| Support Level | N/A | $1.03 |
| Resistance Level | $6.46 | $1.23 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 4.02 | 27.08 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.